DE602006018057D1 - Substituierte chinolone und verwendungsverfahren - Google Patents

Substituierte chinolone und verwendungsverfahren

Info

Publication number
DE602006018057D1
DE602006018057D1 DE602006018057T DE602006018057T DE602006018057D1 DE 602006018057 D1 DE602006018057 D1 DE 602006018057D1 DE 602006018057 T DE602006018057 T DE 602006018057T DE 602006018057 T DE602006018057 T DE 602006018057T DE 602006018057 D1 DE602006018057 D1 DE 602006018057D1
Authority
DE
Germany
Prior art keywords
substituted
chinolines
use process
compounds
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006018057T
Other languages
English (en)
Inventor
Anita Melikian
John Jessen Wright
Antoni Krasinski
Cheng Hu
Aaron Novack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemocentryx Inc
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of DE602006018057D1 publication Critical patent/DE602006018057D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
DE602006018057T 2005-11-10 2006-11-13 Substituierte chinolone und verwendungsverfahren Active DE602006018057D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73569205P 2005-11-10 2005-11-10
PCT/US2006/044149 WO2007059108A2 (en) 2005-11-10 2006-11-13 Substituted quinolones and methods of use

Publications (1)

Publication Number Publication Date
DE602006018057D1 true DE602006018057D1 (de) 2010-12-16

Family

ID=38049231

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006018057T Active DE602006018057D1 (de) 2005-11-10 2006-11-13 Substituierte chinolone und verwendungsverfahren

Country Status (11)

Country Link
US (1) US7557213B2 (de)
EP (2) EP1954274B8 (de)
JP (1) JP5175207B2 (de)
AT (1) ATE486875T1 (de)
AU (1) AU2006315514B2 (de)
CA (1) CA2629461C (de)
DE (1) DE602006018057D1 (de)
DK (1) DK1954274T3 (de)
ES (1) ES2353549T3 (de)
HK (1) HK1121075A1 (de)
WO (1) WO2007059108A2 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2629461C (en) 2005-11-10 2016-01-12 Anita Melikian Substituted quinolones and methods of use
JP5564249B2 (ja) * 2006-06-23 2014-07-30 アレシア・バイオセラピューティクス・インコーポレーテッド 癌に関与するポリヌクレオチド配列およびポリペプチド配列
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
GB0716532D0 (en) 2007-08-24 2007-10-03 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2009036341A2 (en) * 2007-09-14 2009-03-19 The Regents Of The University Of Michigan Compositions and methods relating to hiv protease inhibition
AU2009241392A1 (en) * 2008-05-01 2009-11-05 Merck Sharp & Dohme Corp. 4-oxo-1,4-dihydroquinoline M1 receptor positive allosteric modulators
RU2010151725A (ru) 2008-05-16 2012-06-27 Аблинкс Нв (Be) Аминокислотные последовательности, направленные против cхcr4 и других gpcr, и соединения, включаюшие их
EP2362908A4 (de) 2008-11-03 2013-09-18 Alethia Biotherapeutics Inc Antikörper für die spezifische blockierung der biologischen aktivität eines tumorantigens
DK2349273T3 (en) * 2008-11-04 2015-07-13 Chemocentryx Inc Modulators of CXCR7
US20110014121A1 (en) * 2008-11-04 2011-01-20 Chemocentryx, Inc. Modulators of cxcr7
US8853202B2 (en) * 2008-11-04 2014-10-07 Chemocentryx, Inc. Modulators of CXCR7
PE20120493A1 (es) 2009-06-29 2012-05-20 Incyte Corp Pirimidinonas como inhibidores de pi3k
US8759359B2 (en) * 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
US8680108B2 (en) * 2009-12-18 2014-03-25 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
CA2796311A1 (en) 2010-04-14 2011-10-20 Incyte Corporation Fused derivatives as pi3k.delta. inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
BR112013003631B1 (pt) 2010-08-18 2021-10-13 Samumed, Llc Beta- e gama-dicetonas e gama-hidroxicetonas e composições farmacêuticas que as compreendem
AR084366A1 (es) 2010-12-20 2013-05-08 Incyte Corp N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EP2963039A1 (de) * 2011-02-24 2016-01-06 The Regents of The University of California Kleine moleküle zur endothelzellaktivierung
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
GB201104600D0 (en) 2011-03-18 2011-05-04 Pronoxis Ab New compounds and medical uses
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
AU2012234284B2 (en) 2011-03-28 2015-10-08 Ablynx Nv Bispecific anti-CXCR7 immunoglobulin single variable domains
CA2888908A1 (en) 2011-03-31 2012-10-04 Alethia Biotherapeutics Inc. Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
KR101982475B1 (ko) 2011-09-02 2019-05-27 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
JP6282597B2 (ja) 2012-01-09 2018-02-21 アー・デー・ツェー・セラピューティクス・エス・アー 乳癌を治療する方法
US9403802B2 (en) 2012-03-02 2016-08-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use therefor
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
JP6211530B2 (ja) 2012-11-19 2017-10-11 武田薬品工業株式会社 含窒素複素環化合物
ES2681593T3 (es) 2012-11-29 2018-09-14 Chemocentryx, Inc. Antagonistas de CXCR7
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
KR102252567B1 (ko) 2013-02-22 2021-05-17 사뮤메드, 엘엘씨 Wnt/베타-카테닌 신호전달 경로 활성자로서 감마-디케톤
HUE036571T2 (hu) 2013-04-19 2018-07-30 Incyte Holdings Corp Biciklusos heterociklusok mint FGFR inhibitorok
US9920010B2 (en) * 2013-05-30 2018-03-20 Idorsia Pharmaceuticals Ltd CXCR7 receptor modulators
GB201409044D0 (en) 2014-05-21 2014-07-02 Ucl Business Plc New compounds
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
CN105272964B (zh) * 2014-07-08 2017-11-24 河南省医药科学研究院 6‑取代‑1‑((1‑取代苯基‑1,2,3‑三唑‑4‑基)甲基)‑4‑羰基喹啉‑3‑甲酸乙酯类化合物及其制备和应用
WO2016029021A1 (en) 2014-08-20 2016-02-25 Samumed, Llc Gamma-diketones for treatment and prevention of aging skin and wrinkles
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10202368B2 (en) 2014-12-01 2019-02-12 Idorsia Pharmaceuticals Ltd. CXCR7 receptor modulators
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3259269B9 (de) 2015-02-20 2020-03-04 Incyte Corporation Bizyklische heterozyklen als fgfr inhibitoren
MY187502A (en) 2015-02-27 2021-09-24 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
RU2720205C2 (ru) * 2015-07-17 2020-04-27 Фуджифилм Корпорэйшн Азотсодержащее гетероциклическое соединение
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
CN113194956A (zh) 2018-12-12 2021-07-30 凯莫森特里克斯股份有限公司 用于癌症治疗的cxcr7抑制剂
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN114206338A (zh) 2019-07-10 2022-03-18 凯莫森特里克斯股份有限公司 作为pd-l1抑制剂的二氢化茚类
KR20220100879A (ko) 2019-10-14 2022-07-18 인사이트 코포레이션 Fgfr 저해제로서의 이환식 헤테로사이클
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021102370A1 (en) * 2019-11-21 2021-05-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4379929A (en) 1981-03-19 1983-04-12 Eli Lilly And Company 4(1H)-Oxocinnoline-3-carboxylic acid derivatives
US5116840A (en) 1985-06-13 1992-05-26 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US5034508A (en) 1988-08-31 1991-07-23 Dai-Ichi Kogyo Seiyaku Co., Ltd. Dispersant for nonaqueous systems
AU695132B2 (en) * 1995-08-02 1998-08-06 Darwin Discovery Limited Quinolones and their therapeutic use
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
WO2002094823A1 (en) * 2001-05-24 2002-11-28 Merck Frosst Canada & Co. 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
US7253007B2 (en) 2001-11-30 2007-08-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US8163769B2 (en) 2002-03-12 2012-04-24 Abbott Laboratories Antibacterial compounds
GB0218630D0 (en) 2002-08-10 2002-09-18 Tanabe Seiyaku Co Novel compounds
CN1747929B (zh) * 2002-12-20 2010-04-28 坎莫森特里克斯公司 趋化因子i-tac或sdf-1结合于ccxckr2受体的抑制剂
MXPA05009688A (es) * 2003-03-12 2005-12-05 Abbott Lab Derivados de naftiridina como agentes antibacterianos.
CA2629461C (en) 2005-11-10 2016-01-12 Anita Melikian Substituted quinolones and methods of use

Also Published As

Publication number Publication date
EP1954274A4 (de) 2009-01-07
HK1121075A1 (en) 2009-04-17
EP1954274B1 (de) 2010-11-03
EP2314590A1 (de) 2011-04-27
ATE486875T1 (de) 2010-11-15
US7557213B2 (en) 2009-07-07
AU2006315514B2 (en) 2012-03-01
WO2007059108A3 (en) 2007-12-13
DK1954274T3 (da) 2011-01-31
EP1954274A2 (de) 2008-08-13
ES2353549T3 (es) 2011-03-03
CA2629461A1 (en) 2007-05-24
JP2009515902A (ja) 2009-04-16
EP1954274B8 (de) 2011-01-12
US20070167443A1 (en) 2007-07-19
AU2006315514A1 (en) 2007-05-24
WO2007059108A2 (en) 2007-05-24
CA2629461C (en) 2016-01-12
JP5175207B2 (ja) 2013-04-03

Similar Documents

Publication Publication Date Title
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
CR20130455A (es) Composiciones para el tratamiento de tumores
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
CR8696A (es) Beta-carbolinas utiles para tratar enfermedades inflamatorias
CY1109551T1 (el) Πρωτεασωμικοι αναστολεις και μεθοδοι χρησιμοποιησης αυτων
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
EP1893216A4 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
ATE381558T1 (de) Substituierte pyridinyl und pyrimidinyl derivate als modulatoren eines metabolismus für die behandlung von damit inzusammenhangstehenden krankheiten
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
IL186217A0 (en) Anti-inflammatory modalities
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
NO20082425L (no) Formuleringer omfattende jorumycin-, reni-eramycin-, safracin- eller saframycin-relaterte forbindelser for behandling av proliferative sykdommer
MX2007010484A (es) Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.
CY1111762T1 (el) Διενυδρη παμοϊκη ολανζαπiνη
DE602006013009D1 (de) Pharmazeutische zusammensetzung von mahanin zur behandlung von prostatakrebs
EP1904088A4 (de) Zusammensetzungen und verfahren für die krebsbehandlung
IL185653A (en) Antibodies that call for the 1-kim salt region
EP1865952A4 (de) Histaminhaltige zusammensetzung zur behandlung von allergischen erkrankungen
ATE505195T1 (de) Acylglycerophospholipide zur behandlung von krebs-begleiterscheinungen
ATE511394T1 (de) Verwendung von phthalocyanin-derivaten zur nicht- photodynamischen behandlung von erkrankungen